Teriparatide (PTH 1-34): Bone-Building Peptide Drug

Teriparatide — sold under the brand name Forteo and available in generic form since 2019 — is a 34-amino acid synthetic fragment of endogenous parathyroid hormone (PTH). It is the most powerful anabolic therapy available for osteoporosis, uniquely capable of actually building new bone rather than merely slowing its loss. For patients with severe osteoporosis or high fracture risk, teriparatide represents a mechanistically distinct and clinically superior alternative to antiresorptive agents like bisphosphonates.

Mechanism: Intermittent PTH and Anabolic Signaling

The biological mechanism of teriparatide is elegantly paradoxical. Parathyroid hormone is best known for its role in calcium regulation — when serum calcium drops, PTH is released and mobilizes calcium from bone, effectively breaking it down. Yet when administered intermittently at pharmacological doses (once daily subcutaneous injection), PTH 1-34 produces net bone gain.

This distinction between continuous and intermittent PTH exposure is fundamental. Continuously elevated PTH (as in primary hyperparathyroidism) causes net bone resorption. Intermittent daily pulses of teriparatide preferentially stimulate osteoblasts over osteoclasts — promoting bone formation while suppressing osteoblast apoptosis and increasing osteoblast progenitor differentiation.

The molecular targets include the PTH1R receptor on osteoblasts, which activates cAMP/PKA signaling, upregulates the transcription factors Runx2 and Osterix that drive osteoblast differentiation, and induces IGF-1 and IGF-binding proteins locally in bone. The net result is increased bone modeling on trabecular and cortical surfaces.

Clinical Evidence

The pivotal trial for teriparatide (Neer et al., New England Journal of Medicine, 2001) randomized 1,637 postmenopausal women with prior vertebral fractures to teriparatide 20 mcg/day, 40 mcg/day, or placebo for a median of 21 months. Results were striking: the 20 mcg dose (now standard) reduced new vertebral fractures by 65% and nonvertebral fractures by 53% compared to placebo. Bone mineral density at the lumbar spine increased by 9.7% and at the femoral neck by 2.6%.

Subsequent studies confirmed efficacy in men with osteoporosis and in glucocorticoid-induced osteoporosis, where it outperformed alendronate (a bisphosphonate) in both BMD gain and fracture reduction.

Administration

Teriparatide is administered as a once-daily subcutaneous injection of 20 mcg, typically in the thigh or abdomen, using a prefilled pen injector. The timing of injection (morning vs. evening) does not significantly affect efficacy, though consistent timing is recommended. Patients should be able to sit or lie down for the first hour after injection due to transient orthostatic hypotension in some individuals.

Treatment duration is limited to 24 months in the US (cumulative lifetime exposure) due to the FDA's osteosarcoma risk concern — derived from animal studies showing dose- and duration-dependent osteosarcoma in Fischer 344 rats treated at doses far exceeding human therapeutic levels. Importantly, over two decades of post-marketing surveillance have not shown increased osteosarcoma incidence in human patients.

After completing a teriparatide course, transitioning to an antiresorptive agent (denosumab or bisphosphonate) is essential to preserve the BMD gains, which are otherwise partially lost within 12–18 months of stopping.

Abaloparatide: The Successor Peptide

Abaloparatide (Tymlos) is a synthetic analog of parathyroid hormone-related protein (PTHrP) that acts on the same PTH1R receptor as teriparatide but with a different receptor conformation bias. Clinical trials show comparable vertebral fracture reduction (86% vs 73% in the head-to-head ACTIVE trial) with abaloparatide, and lower hypercalcemia incidence. It may become the preferred anabolic peptide over time.

Cost and Access

Generic teriparatide became available in the US in 2019, significantly reducing cost from the original Forteo price of over $1,000/month. Biosimilar versions (including Bonsity) are now available at substantially lower prices. Insurance coverage for severe osteoporosis with fracture risk is common, though prior authorization is typically required.

FAQ

Who is teriparatide appropriate for? Teriparatide is indicated for postmenopausal women and men with osteoporosis at high fracture risk, those who have failed or cannot tolerate antiresorptive therapy, and patients with glucocorticoid-induced osteoporosis. It requires a physician prescription and monitoring.

Can teriparatide be used more than once in a lifetime? The FDA limits cumulative exposure to 24 months lifetime. Some guidelines now allow a second course after a sufficient interval, but this remains off-label.

Why must I transition to another drug after stopping teriparatide? Teriparatide's bone gains are not fully consolidated at the time of stopping. Without a subsequent antiresorptive agent, BMD declines significantly within 12–18 months as the newly formed bone is resorbed.

Track your supplements in Optimize.